DiaZone-MR 60mg 60mg tablets modified-release

Страна: Армения

Язык: английский

Источник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Активный ингредиент:

gliclazide

Доступна с:

Perdaman Pharmaceuticals Pvt. Ltd.

код АТС:

A10BB09

ИНН (Международная Имя):

gliclazide

дозировка:

60mg

Фармацевтическая форма:

tablets modified-release

Штук в упаковке:

(100/10x10/) in blister

Тип рецепта:

Prescription

Статус Авторизация:

Registered

Дата Авторизация:

2017-12-12

Характеристики продукта

PERDAMAN PHARMACEUTICALS PVT. LTD.
_ _
_ _
_DIAZONE-MR _
_ _
_PAGE 1 OF 7_
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ PAGE 1 OF 7 _
THE SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
DIAZONE-MR
®
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each uncoated modified release tablet contains:
_ACTIVE INGREDIENTS: _
Gliclazide 60 mg
_EXCIPIENTS: _
Lactose, Methacrylic Acid Copolymer, Povidone, Magnesium stearate,
Purified Talc, Isopropyl alcohol
3. PHARMACEUTICAL FORM
Modified-Release Tablets
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Non insulin-dependent diabetes (type 2) in adults when dietary
measures, physical exercise and weight loss
alone are not sufficient to control blood glucose.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Oral use.
For adult use only.
The daily dose may vary from 30 to 120 mg taken orally in a single
intake at breakfast time.
It is recommended that the tablet(s) be swallowed whole.
If a dose is forgotten, there must be no increase in the dose taken
the next day.
As with any hypoglycaemic agent, the dose should be adjusted according
to the individual patient's
metabolic response (blood glucose, HbAlc)
• Initial dose: The recommended starting dose is 30 mg daily.
If blood glucose is effectively controlled, this dose may be used for
maintenance treatment.
If blood glucose is not adequately controlled, the dose may be
increased to 60, 90 or 120 mg daily, in
successive steps. The interval between each dose increment should be
at least 1 month except in patients
whose blood glucose has not reduced after two weeks of treatment. In
such cases, the dose may be
increased at the end of the second week of treatment.
The maximum recommended daily dose is 120 mg.
• Switching from another oral antidiabetic agent to Gliclazide 60 mg
MR Tablets:
Gliclazide 60 mg MR Tablets can be used to replace other oral
antidiabetic agents.
The dosage and the half-life of the previous antidiabetic agent should
be taken into account when switching
to Gliclazide 60 mg MR Tablets.
A transitional period is